Ney Carter Borges: Does APOC3 Inhibition Translates into Structural Coronary Plaque Modification
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“APOC3 Inhibition with Olezarsen and Coronary Atherosclerosis
The Essence – TIMI 73b imaging substudy evaluated whether intensive triglyceride-rich lipoprotein reduction with olezarsen translates into structural coronary plaque modification.
In this randomized, placebo – controlled trial, 468 patients with moderate hypertriglyceridemia and established or high cardiovascular risk underwent serial coronary CT angiography over 12 months.
Olezarsen produced profound lipid changes, including a 63.9% reduction in triglycerides, 71.9% reduction in remnant cholesterol, and a 16% decrease in apolipoprotein B (apoB), without affecting LDL cholesterol.
Despite these robust metabolic effects, the primary endpoint – percent change in noncalcified plaque volume (NCPV) – was not significantly different compared with placebo (Δ +2.98%; 95% CI −3.4 to 9.3; p equals 0.36).
Similarly, no meaningful differences were observed across secondary plaque components, including low-attenuation and total plaque volumes.
These findings highlight a critical mechanistic insight:
Substantial triglyceride and remnant cholesterol reduction alone may be insufficient to induce measurable short – term plaque regression, particularly when apoB lowering is modest.
Given that apoB reflects the total burden of atherogenic particles, the results reinforce its central role in atherosclerosis progression.
Longer – term outcome trials are required to determine whether APOC3 inhibition confers clinical cardiovascular benefit despite neutral imaging findings.”
More posts featuring Ney Carter Borges on Hemostasis Today.
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications